Dr. Jacob Patrick Kelly, MD

Dr. Kelly practices at Alaska Heart Institute in Anchorage, Alaska.

Dr. Kelly's NPI, 1851551949, was assigned on June 11, 2008. Dr. Kelly graduated from University of Colorado School of Medicine, Denver in 2008. Dr. Kelly holds Alaska license 119045.

Dr. Kelly's primary practice is Alaska Heart Institute, at 3841 Piper St, Anchorage, AK 99508 in Anchorage Borough. The practice phone is (907) 561-3211.

Dr. Kelly's primary practice is Alaska Heart Institute in Anchorage, Alaska. Dr. Kelly is also affiliated with Providence Alaska Medical Center. The medical group on file is Alaska Heart & Vascular Institute. Dmand AI also links Dr. Kelly to 4 more hospitals, 5 medical groups and 2 group practices and clinics, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Kelly practices, 7 sites in all. Vendor and product names are available with a free account.

Advanced heart failure and transplant cardiology is Dr. Kelly's primary specialty in the NPI Registry, under taxonomy code 207RA0001X. Dmand AI has Dr. Kelly's licenses on file in 3 states: Alaska, North Carolina and Texas.

CMS data shows 10,906 Medicare services from Dr. Kelly across 36 procedure codes in 2024, for 2,042 Medicare patients. Medicare paid $494,843 for them.

CMS counts 2,042 Medicare patients who saw Dr. Kelly in 2024. The largest group is 65 to 74, with 869 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 24% are also on Medicaid. Their average risk score is 1.69, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Kelly's median patient age at 67, with 40% women.

In 2024, Dr. Kelly wrote 4,404 Medicare Part D claims for 414 patients. 73% of them were for generic drugs. CMS names the drug for 4,092 of them, across 43 drugs with 11 or more claims each, at $1,674,640 in total drug cost. In 2023, CMS named 3,652 claims across 38 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Kelly for performance year 2024, reported as part of a group. Dr. Kelly accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Kelly as offering telehealth.

Dmand AI links 29 papers to Dr. Kelly, published from 2014 to 2021. 2015 was the busiest year, with 7. The most frequent topics are Heart Failure, Stroke Volume and Exercise Test. Dr. Kelly has published most often in Am Heart J. Dr. Kelly's most frequent co-authors are Robert John Mentz, MD, William E. Kraus and Christopher M. O'Connor.

Dmand AI links Dr. Kelly to 1 clinical trial. Conditions studied include Diabetes Mellitus, Type 2 and Diabetes Mellitus. Open Payments lists research payments to Dr. Kelly that name 1 trial.

CMS Open Payments shows 264 general payments to Dr. Kelly from 27 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 77% of the total. Novartis Pharmaceuticals Corporation paid the most, $45,927. It also lists 1 research payment totaling $2,639 in 2024, naming 1 clinical trial.

Dr. Kelly graduated from University of Colorado School of Medicine, Denver in 2008.